Viferon gel 36000ME, 12 g

• As part of the complex therapy of ARVI, incl. flu, frequent and prolonged SARS, incl. complicated by a bacterial infection;

• prevention of ARVI, including influenza;

• as part of the complex therapy of recurrent stenosing laryngotracheobronchitis;

• prevention of recurrent stenosing laryngotracheobronchitis;

• as part of the complex therapy of acute and exacerbations of chronic recurrent herpetic infections of the skin and mucous membranes, incl. urogenital form of herpes infection;

• as part of the complex therapy of herpetic cervicitis.

The drug is used topically and topically.

As part of the complex therapy of ARVI, including influenza, long-term and frequent ARVI, incl. complicated by a bacterial infection: a strip of gel no more than 0.5 cm long is applied to the previously dried surface of the nasal mucosa and / or to the surface of the tonsils 3-5 times / day using a spatula or cotton swab / cotton swab. The course of treatment is 5 days, if necessary, the course can be extended.

Prevention of acute respiratory viral infections, including influenza: during the period of rising incidence, a strip of gel no more than 0.5 cm long is applied to the previously dried surface of the nasal mucosa and / or to the surface of the palatine tonsils 2 times / day for 2-4 weeks.

As part of the complex therapy of recurrent stenosing laryngotracheobronchitis: a strip of gel no more than 0.5 cm long is applied to the surface of the tonsils with a spatula or cotton swab / cotton swab in the acute period of the disease 5 times / day, for 5-7 days, then 3 times / day within the next 3 weeks.

Prevention of recurrent stenosing laryngotracheobronchitis: a strip of gel no more than 0.5 cm long is applied to the surface of the tonsils with a spatula or cotton swab / cotton swab 2 times / day for 3-4 weeks, the courses are repeated 2 times a year.

As part of the complex therapy of acute and chronic recurrent herpetic infection (when the first signs of the disease appear or during the precursor period): a strip of gel no more than 0.5 cm long is applied with a spatula or cotton swab / cotton swab on a previously dried affected surface 3-5 times / day within 5-6 days, if necessary, the duration of the course is increased until the disappearance of clinical manifestations.

As part of the complex therapy of herpetic cervicitis: 1 ml of the gel is applied with a cotton swab on the surface of the cervix, previously cleaned of mucus, 2 times / day for 7 days, if necessary, the duration of the course can be increased to 14 days.

Gel for external and local use in the form of a homogeneous, opaque, gel-like mass of white with a grayish tint.

1 g

interferon alpha-2b human recombinant 36,000 IU

Excipients: ?-tocopherol acetate - 55 mg, benzoic acid - 1.28 mg, sodium tetraborate decahydrate - 1.8 mg, methionine - 1.2 mg, citric acid monohydrate - 1 mg, sodium chloride - 4 mg, human serum albumin solution 10% - 20 mg, glycerol (distilled glycerin) - 20 mg, sodium carmellose - 20 mg, ethanol 95% - 55 mg, purified water - up to 1 g.

Hypersensitivity to the components of the drug.

pharmachologic effect

Interferon. It is a highly purified recombinant protein with a molecular weight of 19,300 daltons. Obtained from the Escherichia coli clone by hybridization of bacterial plasmids with the human leukocyte gene encoding interferon synthesis. Unlike interferon, alpha-2a has arginine at position 23. It has an antiviral effect, which is due to the interaction with specific membrane receptors and the induction of RNA synthesis and, ultimately, proteins. The latter, in turn, interfere with the normal reproduction of the virus or its release. It has immunomodulatory activity, which is associated with the activation of phagocytosis, stimulation of the formation of antibodies and lymphokines. Has an antiproliferative effect on tumor cells

Overdose

Not installed.

Side effect

In rare cases, the development of allergic reactions (skin rashes, itching) is possible.

Interaction with other medicinal products

Not found.

Impact on the ability to drive vehicles and engage in other activities

Not installed.

Application during pregnancy and during breastfeeding

Pregnancy and the period of breastfeeding are not a contraindication for the use of the drug due to the very low absorption of the components. During breastfeeding, do not apply to the area of ??the nipples and areola.